The effect of 50% oxygen on PtCO₂ in patients with stable COPD, bronchiectasis, and neuromuscular disease or kyphoscoliosis: randomised cross-over trials

Janine Pilcher 1,2,3*, Darmiga Thayabaran 1,2, Stefan Ebmeier 1,2, Mathew Williams 1, Geraldine Back 2, Hamish Collie 2, Michael Richards 1,2, Susan Bibby 1,2, Ruth Semprini 1,2, Mark Weatherall 4 and Richard Beasley 1,2,3

Abstract

Background: High-concentration oxygen therapy causes increased arterial partial pressure of carbon dioxide (PaCO₂) in patients with COPD, asthma, pneumonia, obesity and acute lung injury. The objective of these studies was to investigate whether this physiological response to oxygen therapy occurs in stable patients with neuromuscular disease or kyphoscoliosis, and bronchiectasis.

Methods: Three randomised cross-over trials recruited stable patients with neuromuscular disease or kyphoscoliosis (n = 20), bronchiectasis (n = 24), and COPD (n = 24). Participants were randomised to receive 50% oxygen and 21% oxygen (air), each for 30 min, in randomly assigned order. The primary outcome was transcutaneous partial pressure of carbon dioxide (PtCO₂) at 30 min. The primary analysis was a mixed linear model.

Results: Sixty six of the 68 participants had baseline PtCO₂ values < 45 mmHg. The intervention baseline adjusted PtCO₂ difference (95% CI) between oxygen and room air after 30 min was 0.2 mmHg (−0.4 to 0.9), P = 0.40; 0.5 mmHg (−0.2 to 1.2), P = 0.18; and 1.3 mmHg (0.7 to 1.8), P < 0.001, in the neuromuscular/kyphoscoliosis, bronchiectasis and COPD participants respectively.

Conclusions: The small increase in PtCO₂ in the stable COPD patients with high-concentration oxygen therapy contrasts with the marked increases in PaCO₂ seen in the setting of acute exacerbations of COPD. This suggests that the model of studying the effects of high-concentration oxygen therapy in patients with stable respiratory disease is not generalisable to the use of oxygen therapy in the acute clinical setting. Appropriate studies of high-concentration compared to titrated oxygen in acute clinical settings are needed to determine if there is a risk of oxygen-induced hypercapnia in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis.

Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615000970549 Registered 16/9/15, ACTRN12615000971538 Registered 16/9/15 and ACTRN12615001056583 Registered 7/10/15.

Keywords: Bronchiectasis, Carbon dioxide, COPD, Neuromuscular diseases, Oxygen

* Correspondence: Janine.pilcher@mrinz.ac.nz
1 Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242, New Zealand
2 Capital & Coast District Health Board, Wellington, New Zealand
3 Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Oxygen has the potential to elevate arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) in patients with chronic obstructive pulmonary disease (COPD) [1–5]. The incidence and magnitude is variable and it can occur in both stable and acute exacerbations of COPD [1, 5]. Oxygen-induced hypercapnia is likely to be clinically important in the setting of acute exacerbations of COPD. A randomised-controlled trial (RCT) comparing high-concentration and titrated oxygen (to achieve arterial oxygen saturation (SpO<sub>2</sub>) of 88 to 92%) in patients with an acute COPD exacerbation identified an over two-fold increase in mortality with high-concentration oxygen [6]. Consequently oxygen therapy guidelines recommend titration of oxygen therapy within this SpO<sub>2</sub> range in patients with acute exacerbations of COPD, to avoid the risks of both hypoxaemia and hyperoxaemia [2, 3].

A number of mechanisms has been proposed to explain how oxygen therapy increases PaCO<sub>2</sub>. These include a reduction in hypoxic drive to breathe leading to decreased ventilation, and the release of hypoxic pulmonary vasoconstriction leading to worsening of ventilation-perfusion mismatch and increased alveolar deadspace [5, 7]. RCTs report high-concentration oxygen therapy increases PaCO<sub>2</sub> in patients with asthma [8], pneumonia [9], and obesity [10–12]. This suggests oxygen-induced hypercapnia might occur in a range of respiratory conditions with abnormal gas exchange and/or reduced ventilation with respiratory failure.

Neuromuscular disease and kyphoscoliosis can lead to hypoventilation and chronic respiratory failure; airflow obstruction and ventilation-perfusion mismatch are both features of bronchiectasis. As acute respiratory illnesses complicate both of these conditions and can result in hypoxia and the need for oxygen therapy, it is important to establish whether these patients are at risk of oxygen-induced hypercapnia. Two small sleep studies with a total of 17 participants [13, 14] and one exercise study in 22 participants [15] have been performed in patients with cystic fibrosis, which demonstrated average transcutaneous partial pressure of carbon dioxide (PtCO<sub>2</sub>) increases between 4 [15] and 7.5 mmHg [13] during oxygen therapy compared to room air. In patients with neuromuscular disease data are limited to retrospective case examples [16] and a retrospective case series in eight patients with a range of neuromuscular diseases [17]. In the case series, low-flow oxygen (0.5–2 L/min) was associated with an elevation in PaCO<sub>2</sub> by an average 28 mmHg, however the measurements were made up to six days after oxygen therapy.

The purpose of our randomised cross-over trials was to investigate the effects of 50% oxygen compared to 21% oxygen in patients with stable neuromuscular disease or kyphoscoliosis and patients with stable bronchiectasis. To assess the applicability of the results to the clinical setting, we also studied stable COPD patients, matched by severity of airflow obstruction to the bronchiectasis patients. Our hypothesis was that oxygen therapy would increase PtCO<sub>2</sub> in all three trials.

Methods
Overview
This series of three double-blind cross-over trials randomised patients to the order they received 50% oxygen (“oxygen” intervention) and medical grade air containing 21% oxygen (“air” intervention). The trials recruited 20 patients with neuromuscular disease or kyphoscoliosis (Neuromuscular/kyphoscoliosis Study), 24 patients with bronchiectasis (Bronchiectasis Study) and 24 patients with COPD (COPD Study). Each trial was prospectively registered on ANZCTR (ACTRN12615000970549, ACTRN12615000971538 and ACTRN12615001056583, respectively), and had Health and Disability Ethics Committee approval (see Online Supplement). Inclusion and exclusion criteria are presented in Table 1, including the criteria by which Bronchiectasis and COPD participants were matched by airflow obstruction severity.

Potentially eligible patients were recruited through Hutt Valley Hospital, Wellington Regional Hospital and the Medical Research Institute of New Zealand (MRINZ) patient lists, as well as newsletters and posters. Participants attended a single study visit at the MRINZ. After confirming eligibility, study baseline PtCO<sub>2</sub>, heart rate, and SpO<sub>2</sub> were recorded via a SenTec transcutaneous monitor (SenTec AG, Switzerland), and respiratory rate by investigator observation.

Participants were then fitted with a full-face positive airway pressure mask (Respironics), attached to a Douglas Bag (Hans Rudolph) via CO<sub>2</sub>SMO adapter (Novametrix Medical Systems), one-way T valve, respiratory filter (Microgard II, Carefusion), tubing and three-way tap, all connected in series. Participants breathed room air for at least 5 mins to adjust to breathing through the equipment, and then breathed the intervention gas for 30 min. After each intervention, the mask was removed and there was a 30 min observation period breathing room air.

Endpoint measurement
The primary endpoint was PtCO<sub>2</sub> after 30 min.

Heart rate and PtCO<sub>2</sub> were measured via SenTec. Respiratory rate, end tidal carbon dioxide (ETCO<sub>2</sub>), minute ventilation and dead space to tidal volume (VD/VT) were measured via CO<sub>2</sub>SMO (Model 8100), from which the tidal volume, volume of dead space, alveolar volume and alveolar minute ventilation were calculated (see Online Supplement for further detail regarding equipment methodology). Measurements were taken at T = 0
(following mask stabilisation and immediately prior to intervention), and at 10 min intervals during the intervention and observation periods. SpO2 on the SenTec display was covered during the intervention and washout periods to maintain investigator blinding. PtCO2 was monitored continuously; the intervention was stopped if values rose by ≥10 mmHg from T = 0.

The study statistician, who was not involved in study recruitment or visits, created computerised 1:1 randomisation sequences for each study. Randomisation codes were placed in sealed opaque envelopes and opened by the unblinded investigator following T = 0 measurements. The blinded investigator recorded all measurements from this point onwards.

### Analyses

The primary analysis was a mixed linear model with fixed effects for the T = 0 measurements, intervention, and randomisation order, and a random effect for participants to take into account the cross-over design. For all measures an interaction term was tested first to see if there was any difference between the interventions that depended on the time of measurement. As secondary analyses for all outcomes, the differences between interventions at each measurement time were analysed by similarly structured models, with addition of the fixed effect of the time of measurement and a random effect for each participant using a spatial exponential in time repeated measures variance-covariance matrix to account for the cross-over design. The results of this model for PtCO2 were compared between the COPD and Bronchiectasis study participants (as fixed effects), and were also adjusted for forced expiratory volume in one second (FEV1) percentage predicted of 109% or higher, who were matched with COPD participants with an FEV1 percentage predicted of 80% or over (i.e. participants in the mildest COPD severity category based on FEV1) [22].

### Software used

SAS version 9.4 was used.

### Sample size

The intended sample size for each cross-over study was 24 based on 80% power and a type I error rate of 5%, to detect a difference of 2.4 mmHg. This is half the difference found in a study of participants with obesity hypoventilation syndrome which reported a mean (SD) paired difference of 5 (4) mmHg [10].
Results
Participants
Participants were recruited between October 2015 and May 2017 and the CONSORT diagrams are shown in Fig. 1. The Neuromuscular/kyphoscoliosis study recruitment was stopped at 20 participants due to difficulty in recruitment. Participant characterisitics are summarised in Table 2. The COPD group had higher smoking rates than the other two groups, and had similar severity of airflow obstruction as the Bronchiectasis group. One participant in the COPD study had a SpO2 of 87% at study baseline, all other participants had a SpO2 of ≥91%. All study baseline PtCO2 values were < 45 mmHg, with the exception of two participants in the Neuromuscular/kyphoscoliosis group.

PtCO2
PtCO2 rose after the mask was applied in both interventions, returning to study baseline within 10 min of removal. At T = 0, (i.e. after placement and stabilisation of the mask, but prior to receiving the intervention) the average PtCO2 increase was at least 1.3 mmHg higher than the last PtCO2 measurement prior to mask placement (Table 3).

Figure 2 demonstrates PtCO2 over the course of the study (see Online Supplement for individual time point data). The difference (95% CI) in PtCO2 at 30 min between oxygen and room air, adjusted for T = 0 PtCO2, was 0.2 mmHg (−0.4 to 0.9), P = 0.40; 0.5 mmHg (−0.2 to 1.2), P = 0.18; and 1.3 mmHg (0.7 to 1.8), P < 0.001, in the Neuromuscular/kyphoscoliosis, Bronchiectasis and COPD participants respectively (Table 3). PtCO2 did not increase or decrease by ≥4 mmHg from T = 0 during the interventions, with the exception of one Bronchiectasis and one COPD participant, during the oxygen intervention only (increases of 4.8 mmHg and 4.7 mmHg respectively). The interaction terms between the time points (10, 20 and 30 min) were not significantly different. The mixed linear model estimates for the differences in PtCO2 across all time points and adjusted for T = 0 were slightly higher during the oxygen intervention compared to room air in the Bronchiectasis and COPD studies (Table 3). When compared to the Bronchiectasis participants, the COPD participants had a greater mean difference in PtCO2 adjusted for T = 0 between the oxygen and air interventions: 0.90 mmHg (95% CI 0.5 to 1.3), P < 0.001. There was no change to this estimate after incorporation of FEV1 percentage predicted as a potential confounder.

Changes in other respiratory measures
Secondary outcomes are presented in Table 4. In the Bronchiectasis participants, the mean ETCO2 decreased by 1.0 mmHg during the oxygen intervention, compared with air. This was associated with a small increase in dead space (0.01 L) and VD/VT (0.03). In the COPD group the mean ETCO2 decreased by 1.1 mmHg, and this was associated with a small reduction in alveolar minute ventilation (0.21 L/min) and increase in VD/VT (0.023).

Discussion
These randomised cross-over studies have shown that 50% oxygen for 30 min did not result in clinically significant increases in PtCO2 at 30 min in patients with stable COPD, Bronchiectasis or Neuromuscular disease/Kyphoscoliosis. In the patients with stable COPD the mean PtCO2 increase with high-concentration oxygen therapy was 1.3 mmHg; while this was statistically significant, the magnitude of the change is not of clinical

Fig. 1 Flow of participants through studies. BMI: Body mass index, COPD: Chronic obstructive pulmonary disease, CT: Computerised tomography, FEV1: Forced expiratory volume in 1 s, FVC: Forced vital capacity, SNIP: Sniff nasal inspiratory pressure. *Burkholderia or other result at the investigator’s discretion. ** T valve tubing malfunction for 1 participant in the Bronchiectasis study and Sentec maintenance error for 1 participant in the COPD study. See Online Supplement for further detail. See legend of Table 3 and Online Supplement for further N value details.
### Table 2: Participant characteristics and study baseline measurements

| Diagnosis | Neurmuscular disease/ Kyphoscoliosis | Bronchiectasis | COPD |
|-----------|-------------------------------------|----------------|-------|
|           | N = 20<sup>a</sup>                  | N = 24<sup>a</sup> | N = 24<sup>a</sup> |
| Neuromuscular disease: 18  | Bronchiectasis: 24  | COPD: 24  |
| Kyphoscoliosis: 2<sup>b</sup>  | Cystic Fibrosis: 0  |       |
| Male  | 8 (40%)  | 7 (29%)  | 12 (50%)  |
| Home NIV  | 4 (20%)  | 2 (8%)  | 1 (4%)  |
| Home oxygen  | 1 (5%)  | 0 (0%)  | 0 (0%)  |
| Smoking status  | Total N = 18<sup>e</sup>  | Total N = 23<sup>f</sup>  | Total N = 18<sup>e</sup>  |
| - Current  | 1 (6%)  | 0 (0%)  | 3 (17%)  |
| - Ex  | 7 (39%)  | 3 (13%)  | 15 (83%)  |
| - Never  | 10 (56%)  | 20 (87%)  | 0 (0%)  |

#### Mean (SD)

|                | Neurmuscular disease/ Kyphoscoliosis | Bronchiectasis | COPD |
|----------------|-------------------------------------|----------------|-------|
| Age (years)  | 52.2 (14.9)  | 63.0 (12.0)  | 69.4 (7.3)  |
| BMI (kg/m<sup>2</sup>)  | 25.3 (7.2)  | 27.1 (4.7)  | 27.9 (4.8)  |
| Smoking pack years  | 42.9 (11.1)  | 0.6 (2.2)  | 35.5 (22.9)  |
| FEV<sub>1</sub> percentage predicted (%)  | 57.6 (20.5)  | 69.9 (22.4)  | 65.7 (17.3)  |
| FVC percentage predicted (%)  | 57.7 (20.5)  | 87.4 (21.5)  | 97.5 (17.9)  |
| FEV<sub>1</sub>/FVC ratio (%)  | 83.0 (7.3)  | 64.6 (12.2)  | 53.5 (11.1)  |
| PtCO<sub>2</sub> (mmHg)  | 38.7 (4.8)  | 36.6 (3.4)  | 35.7 (3.5)<sup>d</sup>  |
| - Min to max  | 27.8 to 48.6  | 29.3 to 42.8  | 29.8 to 42.1  |
| Oxygen saturation (%)  | 95.7 (2.4)  | 96.3 (1.3)  | 95.4 (2.5)<sup>d</sup>  |
| - Min to max  | 91 to 100  | 93 to 99  | 87 to 99  |
| Respiratory rate (breaths/minute)  | 18.8 (4.5)  | 16.8 (3.2)  | 17.0 (3.9)  |

#### Neuromuscular disease/kyphoscoliosis study entry criteria and diagnoses, N

|                | Neurmuscular disease/ Kyphoscoliosis | Bronchiectasis | COPD |
|----------------|-------------------------------------|----------------|-------|
| Participants with SNIP < 95% range<sup>e</sup>  | 12  | NA  | NA  |
| Participants with VC drop ≥10% sitting to lying<sup>f</sup>  | 13  | NA  | NA  |

#### Neuromuscular Diagnosis

- Charcot Marie Tooth 3
- Facioscapulohumeral muscular dystrophy 2
- Limb girdle muscular dystrophy 1
- Motor neurone disease 5
- Multiple sclerosis 1
- Myotonic dystrophy 4
- Phrenic nerve palsy 1
- Tetraplegia 1

---

**COPD**: Chronic Obstructive Pulmonary Disease, **BMI**: Body mass index, **FEV<sub>1</sub>**: Forced expiratory volume in 1 s, **FVC**: Forced vital capacity, **NA**: Not applicable, **NIV**: Non-invasive ventilation, **PtCO<sub>2</sub>**: Transcutaneous partial pressure of carbon dioxide, **SNIP**: Sniff nasal inspiratory pressure, **VC**: Vital capacity (slow)

<sup>a</sup> Unless otherwise stated

<sup>b</sup> One kyphoscoliosis participant also had Ehlers-Danlos Syndrome, and meet both the spirometry and SNIP entry criteria for neuromuscular disease patients

<sup>c</sup> Data unavailable from some participants. In the COPD study six participants did not report whether they were current or ex smokers, however all had pack year histories of at least 19 years

<sup>d</sup> N = 23, data unavailable due to SenTec failure, see Fig. 1 and Online Supplement for details

<sup>e</sup> Total N in which data was measured = 19

<sup>f</sup> Total N in which data was measured = 18

See Online Supplement for ethnicity and respiratory comorbidity data
significance. This is in contrast with the marked increases in PaCO₂ seen in the setting of acute exacerbations of COPD [1, 5, 6]. This suggests that the results of all three studies in stable patients are unlikely to be generalisable to the use of oxygen therapy in the acute clinical setting.

To our knowledge there have been no RCTs investigating the effects of oxygen on PaCO₂ in acutely unwell patients with neuromuscular disease, kyphoscoliosis or bronchiectasis. However the risk of oxygen-induced hypercapnia has been well established through RCTs comparing high-concentration and titrated oxygen regimens in patients with acute COPD exacerbations [6]. We undertook the current studies in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis while stable, recognising that the results from stable patients in the laboratory setting may not translate to the clinical setting. We therefore conducted the study in COPD patients, as a comparator group in which clinically relevant oxygen-induced PaCO₂ elevations have been demonstrated [1, 5, 6]. The study baseline SpO₂ and PtCO₂ values were comparable across all three studies, and FEV₁ percentage predicted matching between the COPD and Bronchiectasis patients ensured recruitment of patients with similar physiological impairment in terms of airflow obstruction. Contrary to findings in the acute setting [1, 5, 6], oxygen administration did not result in a clinically significant change in PtCO₂ in the stable COPD patients, indicating that the study model was not an appropriate method to detect the potential for oxygen-induced hypercapnia in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis in clinical practice.

A number of factors may explain the minimal PtCO₂ change in the COPD participants. Firstly, oxygen delivery was via a closed-circuit system, rather than standard mask used in clinical practice. This ensured precise fraction of inspired oxygen (FiO₂) administration and allowed deadspace and ventilation measurement. However, this method of delivery may have affected participant’s responses to the interventions, particularly as breathing through the study mask consistently resulted in a small increase in PtCO₂. Secondly, the studies were conducted in stable, rather than acutely unwell, patients.

### Table 3 Transcutaneous carbon dioxide outcomes

|                                      | Neuromuscular disease/ Kyphoscoliosis | Bronchiectasis | COPD |
|--------------------------------------|---------------------------------------|----------------|------|
|                                      | N = 20a                                | N = 24a        | N = 24a        |
| **Change in PtCO₂ on placement of mask** |                                       |                |                 |
| Mean (SD), mmHg                       |                                       |                |                 |
| Intervention 1                        | 1.8 (2.8)                             | 1.3 (1.7)      | 1.3 (1.4)      |
| Intervention 2                        | 1.3 (1.1)d                            | 2.0 (1.4)f     | 1.8 (1.4)f     |
| **PtCO₂ during air and oxygen interventions** |                                     |                |                 |
| Mean (SD), mmHg                       |                                       |                |                 |
| Oxygen T = 0                          | 39.4 (4.2)d                           | 38.5 (2.6)     | 37.0 (3.2)f    |
| Oxygen T = 30                         | 40.3 (4.1)d                           | 39.6 (2.8)e    | 38.8 (3.5)f    |
| Air T = 0                             | 40.2 (5.6)                            | 38.6 (2.7)f    | 37.3 (3.5)f    |
| Air T = 30                            | 39.7 (3.6)e                           | 38.9 (2.9)f    | 37.7 (3.3)f    |
| **Mixed linear model estimates**      |                                       |                |                 |
| (95% CI), mmHg                        |                                       |                |                 |
| Change at 30 min, oxygen minus air    | 0.2 (−0.4 to 0.9)                      | 0.5 (−0.2 to 1.2) | 1.3 (0.7 to 1.8) |
| P = 0.40                              |                                       | P = 0.18       | P < 0.001      |
| Change over duration of intervention, oxygen minus air | -0.07 (−0.40 to 0.27) | 0.4 (0.08 to 0.7) | 1.3 (1.0 to 1.5) |
| P = 0.70                              |                                       | P = 0.012      | P < 0.001      |

*Unless otherwise stated

bChange is PtCO₂ at T = 0 minus last recorded PtCO₂ value prior to placement of mask

aN = 17

bN = 18

N = 22

N = 23

* Mixed linear model values represent oxygen minus air change from T = 0

# Incorporates values from T = 10, 20 and 30 min. The interaction between each time point (10, 20 and 30 min) was not significantly different, see Online Supplement for P values. N values for PtCO₂ at each time point during the study were as follows:

- Neuromuscular/Kyphoscoliosis study oxygen intervention/washout: n = 18 at T = 0 to T = 50, n = 17 at T = 60
- Neuromuscular/Kyphoscoliosis study air intervention/washout: n = 20 at T = 0, n = 19 at T = 10, n = 18 at T = 20 and n = 17 at all other time points
- Bronchiectasis study oxygen intervention/washout: n = 24 at T = 0 and T = 10, n = 23 at T = 20, n = 22 at all other time points
- Bronchiectasis study air intervention/washout: n = 23 at T = 0 to T = 50 and n = 23 at T = 60
- COPD oxygen and air interventions/washouts: n = 23 at all time points

See Online Supplement for further N value details
This allowed randomised cross-over trial design and meant that participants were more likely to tolerate study procedures. However, the physiological response to oxygen in stable patients may not translate to the acute setting. Previous studies investigating oxygen delivery to stable COPD patients have had variable results, ranging from no or small changes in mean PaCO$_2$ or PtCO$_2$ [24–31] to marked increases [23, 32–38]. Two studies have compared the effects of identical oxygen regimens in patients when having an acute exacerbation of their respiratory disease and when stable. Rudolf et al. found that an FiO$_2$ of up to 0.28 for 1 h increased PaCO$_2$ by 9, 15 and 31 mmHg compared with air in three patients with exacerbation of chronic respiratory failure [39]. However, the same oxygen regimen did not alter PaCO$_2$ more than 3 mmHg when the same patients were stable. Similarly, Aubier et al. found 30 min of oxygen via a mouthpiece increased average PaCO$_2$ by 10.1 mmHg in 12 patients during a COPD exacerbation [25]. It increased by only 2.8 mmHg when the same patients were stable. The differences in response between acute and stable disease may relate to lower tidal volumes and/or a greater degree of hypoxic pulmonary vasoconstriction and ventilation/perfusion mismatch that occur in acute COPD exacerbation, which are further modified by oxygen therapy [40, 41]. Additionally, acutely unwell patients are more likely to have lower SpO$_2$ levels and elevated PaCO$_2$ levels. While hypercapnia and hypoxaemia are not necessarily prerequisites for oxygen-induced hypercapnia [38, 42], both have been associated with increased likelihood and magnitudes of oxygen-induced elevations in PaCO$_2$ [10, 12, 23, 25, 33, 38]. In support of this, previous studies in stable COPD demonstrating significant oxygen-induced increases in PaCO$_2$ have had participants with lower baseline blood oxygen levels [32, 34, 35, 38], and/or higher baseline PaCO$_2$ values [23, 32–38] than the participants in the current three studies. Additionally, only one of the participants, from the COPD study, had a study baseline SpO$_2$ of 87%. All other participants had saturations ≥91%, meaning they were well above the SpO$_2$ level at which initiation of oxygen therapy is recommended in the acute clinical setting [2, 3].

Oxygen therapy has previously been demonstrated to increase VD/VT [10, 11, 23, 27, 35] and reduce ETCO$_2$ [43]. However, caution is needed in interpreting the small increases in VD/VT and reductions in ETCO$_2$ during the oxygen intervention in the Bronchiectasis and COPD studies. These values were recorded by CO$_2$SMO and increased oxygen concentrations in the respiratory circuit could systematically decrease the displayed ETCO$_2$ while still keeping it within the manufacturer’s error range of up to 5% (User manual Oct 10, 1997). This decrease could explain the small changes in VD/VT and ETCO$_2$ observed.
There are a number of methodological issues relevant to interpretation of the study findings. Transcutaneous monitoring was used as a surrogate for PaCO₂ by arterial blood gas (ABG). ABGs and capillary blood gas sampling were not used to measure PaCO₂ during the interventions as they do not provide continuous measurement and cause discomfort. Additionally, ABG sampling carries risk of ischaemia. Our study outcome measures were change in PtCO₂ over time, which the SenTec has been demonstrated to accurately determine [44, 45], with an estimate of bias for change in PtCO₂ of −0.03 mmHg (95% CI −0.44 to 0.38) \( p = 0.89 \) when compared to arterialised blood gas values in COPD patients [45]. Only 20 participants were recruited to the Neuromuscular/kyphoscoliosis study, however this did not affect the power to detect a difference in PtCO₂ between the interventions, given the SD was lower than that used for sample size calculation.

**Conclusion**

Delivery of 50% oxygen for 30 min did not result in a clinically significant increase in PtCO₂ in stable outpatients with neuromuscular disease, kyphoscoliosis, bronchiectasis or COPD. This indicates the model used is an inappropriate method for evaluating the risks of oxygen-induced hypercapnia in the acute clinical setting and highlights the limitations of interpreting results from studies in stable patients in the laboratory setting. It is recommended that future studies into the risks of oxygen-induced hypercapnia are undertaken through comparison of high-concentration oxygen to titrated
oxygen in the acute respiratory illnesses that complicate neuromuscular disease, kyphoscoliosis and bronchiectasis. In the interim, current evidence of the potential for oxygen-induced hypercapnia to occur across a range of respiratory conditions [6, 8, 9, 12] supports guideline recommendations to titrate oxygen therapy in all patients to avoid the risks of hyperoxaemia as well as hypoxaemia.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12890-020-1132-z.

Additional file 1.

Abbreviations
BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; CT: Computed Tomography; ETCO2: End Tidal Carbon Dioxide; FEV1: Forced Expiratory Volume in 1 s; FiO2: Fraction of Inspired Oxygen; FVC: Forced Vital Capacity; MRINZ: Medical Research Institute of New Zealand; PaCO2: Arterial Partial Pressure of Carbon Dioxide; PaO2: Arterial Partial Pressure of Oxygen; PetCO2: Transcutaneous Partial Pressure of Carbon Dioxide; RCT: Randomised Controlled Trial; SNIP: Sniff Nasal Inspiratory Pressure; SpO2: Oxygen Saturation; VC: Vital Capacity (slow); VD/VT: Ratio of Dead Space to Tidal Volume

Acknowledgements
We would like to give special thanks to all of the participants for their involvement in our study. Leonie Eastlake, James Gilchrist, Emily Tweedale, Joe Singer and Alice McDouall (all of the Medical Research Institute of New Zealand) were all investigators who made significant contributions to the conduct of one or more of the studies.

Authors’ contributions
RB was the principal investigator for the study, is guarantor for the study, and affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. DT, SE, MW1, GB, HC, MR, SB, RS and JP were investigators on the study and collected the data. MW2 performed the statistical analysis. JP wrote the first draft of the manuscript. JP and RB conceived the study and wrote the first draft of the protocol. All authors contributed to study design, interpretation of results, manuscript writing, and reviewed the final manuscript prior to submission. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. No writing assistance was received.

Funding
The studies received funding from the Health Research Council of New Zealand (Independent Research Organisations Capability Fund and Clinical Research Fellowship for JP) and Capital and Coast District Health Board. The Neuromuscular/kyphoscoliosis disease study specifically received funding from the Neuromuscular Research Foundation Trust, funded by the Richdale Charitable Trust. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics approval was obtained from the Health and Disability Ethics Committee, New Zealand (References: Neuromuscular disease/ Kyphoscoliosis CEN/11/11/065; Bronchiectasis CEN/11/12/075; COPD 13/STH/200). Written informed consent was obtained before any study-specific procedures. No participant was under the age of 16.

Consent for publication
Not applicable.

Competing interests
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. All authors have no competing interests to declare, other than the MRINZ receiving research funding from Health Research Council of New Zealand.

Author details
1Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242, New Zealand. 2Capital & Coast District Health Board, Wellington, New Zealand. 3Victoria University of Wellington, Wellington, New Zealand. 4University of Otago Wellington, Wellington, New Zealand.

Received: 5 December 2019 Accepted: 3 April 2020
Published online: 07 May 2020

References
1. Murphy R, Driscoll P, O’Driscol R. Emergency oxygen therapy for the COPD patient. Emerg Med J. 2001;18:333–9.
2. O’Driscoll BR, Howard LS, Ears J, Mak V, British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72:1–190.
3. Beasley R, Chien J, Douglas J, Eastlake L, Farah C, King G, Moore R, Pilcher J, Richards M, Smith S, Walters H. Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: ‘swimming between the flags’. Respirology. 2015;20:1182–91.
4. Pilcher J, Perrin K, Beasley R. The effect of high concentration oxygen therapy on PaCO2 in acute and chronic respiratory disorders. Transl Respir Med. 2013;1:1–3.
5. Pilcher J, Weatherall M, Perrin K, Beasley R. Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015;9:287–93.
6. Austin MA, Wills KE, Blizard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462.
7. New A. Oxygen: kill or cure? Prehospital hyperoxia in the COPD patient. Emerg Med J. 2006;23:144–6.
8. Perrin K, Wijesinghe M, Healy B, Wadsworth K, Bowditch R, Babbys B, Baker T, Weatherall M, Beasley R. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax. 2011;66:937–41.
9. Wijesinghe M, Perrin K, Healy B, Weatherall M, Beasley R. Randomised controlled trial of high concentration oxygen in suspected community-acquired pneumonia. J R Soc Med. 2011;105:208–16.
10. Wijesinghe M, Williams M, Perrin K, Weatherall M, Beasley R. The effect of supplemental oxygen on hypercapnia in subjects with obesity-associated hypoventilation: a randomized, crossover, clinical study. Chest. 2011;139:1018–24.
11. Hollier CA, Harmer AR, Maxwell LJ, et al. Moderate concentrations of supplemental oxygen worsen hypercapnia in obesity hypoventilation syndrome: a randomised crossover study. Thorax. 2014;69:346–53.
12. Pilcher J, Richards M, Eastlake L, McKinstry SJ, Barham S, Jefferys S, Braithwaite I, Weatherall M, Beasley R. High flow or titrated oxygen for obese medical inpatients: a randomised crossover trial. Med J Aust. 2017;207:430–4.
13. Gozal D. Nocturnal ventilatory support in patients with cystic fibrosis: comparison with supplemental oxygen. Eur Respir J. 1997;10:1099–2003.
14. Spier S, Rivlin J, Hughes D, Levison H. The effect of oxygen on sleep, blood gases, and ventilation in cystic fibrosis. Am Rev Respir Dis. 1984;129:712–8.
15. Marcus CL, Bader O, Stabile MW, Wang Q, Osher AB, Keens TG. Supplemental oxygen and exercise performance in patients with cystic fibrosis with severe pulmonary disease. Chest. 1992;101:52–7.
16. Chiu M, Bach JR, Saporito R, Albert O. Quantitation of oxygen-induced hypercapnia in respiratory pump failure. Revista Portuguesa de Pneumologia (English Edition). 2016;22:262–5.
17. Gay PC, Edmonds LC. Severe hypercapnia after low-flow oxygen therapy in patients with neuromuscular disease and diaphragmatic dysfunction. Mayo Clin Proc. 1995;70:327–30.
18. Johnston CE, Richards BS, Sucato DJ, Bidwell KH, Lenke LG, Erickson M. Correlation of preoperative deformity magnitude and pulmonary function tests in adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2011;36:1096–102.
19. Benditt J, Botano L. Pulmonary issues in patients with chronic neuromuscular disease. Am J Respir Crit Care Med. 2013;187:1046–55.
20. Uldry C, Fitting JW. Maximal values of sniff nasal inspiratory pressure in healthy subjects. Thorax. 1995;50:371–5.
21. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. General considerations for lung function testing. Eur Respir J. 2005;26:153–61.
22. NICE guidelines. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Clinical guideline published: 23 June 2010. https://www.nice.org.uk/guidance/cg101/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-mana. Accessed Apr 2020.
23. O’Donnell DE, D’Angiyou F, Fitzpatrick M, Webb KA. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med. 2002;166:663–8.
24. Mithoefer JC, Karetzky MS, Mead GD. Oxygen therapy in respiratory failure. N Engl J Med. 1967;277:947–9.
25. Aubier M, Mucino D, Fournier M, Milic-Emili J, Parietie R, Derenne JP. Central respiratory drive in acute respiratory failure of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980;122:191–9.
26. Mithoefer JC, Keighley JF, Cook WR. The AaDO2 and venous admixture at varying inspired oxygen concentrations in chronic obstructive pulmonary disease. Crit Care Med. 1978;6:131–5.
27. Castaing Y, Manier G, Guenard H. Effect of 26% oxygen breathing on gas exchange in patients with chronic obstructive pulmonary disease. Eur Respir J. 1992;5:525–30.
28. Mithoefer JC, Karetzky MS, Mead GD. Oxygen therapy in respiratory failure. N Engl J Med. 1967;277:947–9.
29. Saadjian AY, Philip-Joet FF, Levy S, Amaud AG. Effect of almitrine bismesylate on pulmonary vasoreactivity to hypoxia in chronic obstructive pulmonary disease. Eur Respir J. 1994;7:862–8.
30. King A, Cooke N, Leitch A, Flenley D. The effects of 30% oxygen on the respiratory response to treadmill exercise in chronic respiratory failure. Clin Sci. 1973;44:151–62.
31. Schif MM, Massaro D. Effect of oxygen administration by a Venturi apparatus on arterial blood gas values in patients with respiratory failure. N Engl J Med. 1967;277:950–3.
32. Lopez-Majano V, Dutton RE. Regulation of respiration during oxygen breathing in chronic obstructive lung disease. Am Rev Respir Dis. 1973;108:232–40.
33. Prime FJ, Westlake BK. The respiratory response to CO2 in emphysema. Clin Sci. 1954;13:321–32.
34. Sassoon CS, Hassell KT, Mahutte CK. Hyperoxic-induced hypercapnia in stable chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987;135:907–11.
35. Vos PJ, Folgering HT, de Boo TM, Lemmens WJ, van Herwaarden CL. Effects of chloromadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J. 1994;7:850–5.
36. Bone RC, Pierce AK, Johnson RL Jr. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. Am J Med. 1978;65:896–902.
37. Chiang IL, Hung TC, Ho SC, Lin HC, Yu CT, Wang CH, Kuo HP. Respiratory response to carbon dioxide stimulation during low flow supplemental oxygen therapy in chronic obstructive pulmonary disease. J Formosan Med Assoc. 2002;101:607–15.
38. Rudolf M, Banks RA, Semple SJ. Hypercapnia during oxygen therapy in acute exacerbations of chronic respiratory failure. Hypoxia revisited. Lancet (London, England). 1977;2:483–6.
39. Calverley PM. Respiratory failure in chronic obstructive pulmonary disease. Eur Respir J. 2003;19(5Suppl):26–30s.
40. Stradling JR. Hypercapnia during oxygen therapy in airways obstruction: a reappraisal. Thorax. 1986;41:897–902.
41. Bardsley G, Pilcher J, McKinstry S, Shintcliffe P, Berry J, Fingleton J, Weatherall M, Beasley R. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. BMC Pulmonary Medicine. 2018. https://doi.org/10.1186/s12890-018-0720-7.
42. Yamauchi H, Ito S, Sasano H, Haimi T, Fisher J, Sobue K. Dependence of the gradient between arterial and end-tidal P CO2 on the fraction of inspired oxygen. Br J Anaesth. 2011;107:631–5.
43. Rodriguez P, Lellouche F, Aboab J, Blusson CB, Brochard L. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adult patients. Intens Care Med. 2006;32:309–12.
44. Fingleton J, McKinstry S, Pilcher J, Weatherall M, Beasley R, Bardsley G. Accuracy of transcutaneous carbon dioxide measurement for change over time. Respirology. 2017;22:18–100. https://doi.org/10.1111/resp.13009.